Report copyright - The BTK Inhibitor ARQ 531 Targets Ibrutinib-Resistant CLL ... · ARQ 531 Is a Potent Inhibitor of BCR Signaling ARQ 531 was designed as a reversible, orally bioavailable, ATP-competitive
Please pass captcha verification before submit form